SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits

Neal M Dixit; Boback Ziaeian; Gregg C Fonarow

doi:10.1016/j.hfc.2022.03.003

SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits

Heart Fail Clin. 2022 Oct;18(4):587-596. doi: 10.1016/j.hfc.2022.03.003.

Authors

Neal M Dixit¹, Boback Ziaeian², Gregg C Fonarow³

Affiliations

¹ Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: https://twitter.com/NealDixit.
² Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Cardiology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. Electronic address: https://twitter.com/boback.
³ Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: gfonarow@mednet.ucla.edu.

PMID: 36216488
DOI: 10.1016/j.hfc.2022.03.003

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a recent addition to the pillars of medical therapy for heart failure (HF) with reduced ejection fraction, all of which improve quality of life, morbidity, and mortality. These benefits are evident within the first 30 days of initiation. This review discusses the rationale for SGLT2i initiation in simultaneous or in rapid sequence with other guideline-directed medical therapy (GDMT). We also discuss SGLT2i use and early benefits in HF patients with an ejection fraction greater than 40%.

Keywords: Guideline-directed medical therapy; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction; Initiation and sequencing.

Publication types

Review

MeSH terms

Heart Failure* / drug therapy
Humans
Quality of Life
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Stroke Volume

Substances

Sodium-Glucose Transporter 2 Inhibitors